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Abstract
Background: When patients are asked what they find most anxiety provoking about having
surgery, the top concerns almost always include postoperative nausea and vomiting (PONV). Only
until recently have there been any published recommendations, mostly derived from expert
opinion, as to which regimens to use once a patient develops PONV. The goal of this study was to
assess the responses to a written survey to address the following questions: 1) If no prophylaxis is
administered to an ambulatory patient, what agent do anesthesiologists use for treatment of PONV
in the ambulatory Post-Anesthesia Care Unit (PACU)?; 2) Do anesthesiologists use non-
pharmacologic interventions for PONV treatment?; and 3) If a PONV prophylaxis agent is
administered during the anesthetic, do anesthesiologists choose an antiemetic in a different class
for treatment?
Methods:  A questionnaire with five short hypothetical clinical vignettes was mailed to 300
randomly selected USA anesthesiologists. The types of pharmacological and nonpharmacological
interventions for PONV treatment were analyzed.
Results: The questionnaire was completed by 106 anesthesiologists (38% response rate), who
reported that on average 52% of their practice was ambulatory. If a patient develops PONV and
received no prophylaxis, 67% (95% CI, 62% – 79%) of anesthesiologists reported they would
administer a 5-HT3-antagonist as first choice for treatment, with metoclopramide and
dexamethasone being the next two most common choices. 65% (95% CI, 55% – 74%) of
anesthesiologists reported they would also use non-pharmacologic interventions to treat PONV in
the PACU, with an IV fluid bolus or nasal cannula oxygen being the most common. When PONV
prophylaxis was given during the anesthetic, the preferred PONV treatment choice changed.
Whereas 3%–7% of anesthesiologists would repeat dose metoclopramide, dexamethasone, or
droperidol, 26% (95% confidence intervals, 18% – 36%) of practitioners would re-dose the 5-HT3-
antagonist for PONV treatment.
Conclusion: 5-HT3-antagonists are the most common choice for treatment of established PONV
for outpatients when no prophylaxis is used, and also following prophylactic regimens that include
a 5HT3 antagonist, regardless of the number of prophylactic antiemetics given. Whereas 3% – 7%
of anesthesiologists would repeat dose metoclopramide, dexamethasone, or droperidol, 26% of
practitioners would re-dose the 5-HT3-antagonist for PONV treatment.
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Background
When patients are asked what they find most anxiety pro-
voking about having surgery, the top concerns almost
always include postoperative nausea and vomiting
(PONV) [1,2]. Anesthesiologists agree that PONV is an
important issue for patients [3]. Since PONV is important
to patients, improving the quality of anesthesia care
includes reducing the incidence and severity of PONV. A
large number of prospective randomized clinical trials
have been completed to evaluate the efficacy of drugs and
non-pharmacologic interventions to prevent PONV [4-8].
Data also exist on what prophylaxis interventions
anesthesiologists in routine clinical practice actually
administer for PONV [9].
However, fewer studies investigate the efficacy of
antiemetics for the treatment of PONV once it occurs in
the Post Anesthesia Care Unit (PACU). For example, a
quantitative systematic review of treatment of established
PONV published in 2001 found that metoclopramide,
droperidol, isopropyl alcohol vapor, and midazolam were
tested in one trial only, each with a limited number of
patients [10]. That review also found that 5-HT3 antago-
nists had absolute risk reductions compared with placebo
of 20% – 30%, with a less pronounced anti-nausea effect.
The discrepancy between the plethora of trials on preven-
tion of PONV and the paucity of trials on treatment of
established symptoms is due, in part, to the difficulty in
performing PONV treatment studies since a large number
of patients would be needed to obtain the required target
sample size that eventually experience PONV. In fact, only
until recently, have there been any published recommen-
dations, mostly derived from expert opinion not clinical
trials, as to which regimens to use once a patient develops
PONV [11].
Few USA data exist on practice patterns for treatment of
PONV once it occurs in the PACU. PONV treatment data
could be collected prospectively or abstracted retrospec-
tively from the anesthesia and medical record. However,
these methods make it difficult to compare practice pat-
terns among practitioners, as neither method controls for
differences in patient's severity of illness, demographics,
or practice type. Other disadvantages of the chart review
methodology include recording bias (e.g., some interven-
tions may be provided but not documented) and the
skilled (and costly) experts required to accurately collect
data from the medical record.
To isolate physician practice from confounding variables,
simple case vignettes have been validated as a method to
elicit medical practice treatment patterns [12]. Vignettes
are written cases that simulate actual clinical practice.
Educators, demographers, and health service researchers
have used these vignettes to measure processes in a wide
range of settings [13-15].
The goal of this study was to assess the responses to a writ-
ten questionnaire (with short hypothetical clinical
vignettes) to address the following questions regarding
PONV in the PACU: 1) If no prophylaxis is administered
to an ambulatory patient, what agent do anesthesiologists
use for treatment?; 2) Do anesthesiologists use non-phar-
macologic interventions for PONV treatment?; and 3) If a
PONV prophylaxis agent is administered during the anes-
thetic, do anesthesiologists choose an antiemetic in a dif-
ferent class for treatment?
Methods
Approval for this study was obtained from the Stanford
University Human Subjects Committee.
Physician sample
We mailed a written questionnaire to 300 anesthesiolo-
gists selected at random from the 2002 American Society
of Anesthesiology Directory available to us in printed
form. A random number generator was used to select
names, the number indicating how far down the list to go
on each page. We chose 300 because based on previous
studies, we expected approximately a 33% response rate,
which would generate our goal of 100 surveys returned.
Questionnaires were sent by U.S. mail to each subject's
address during December 2004. A stamped self-addressed
envelope was to enhance the response rate.
Survey measurement methods
The survey instrument consisted of three parts. The first
page was a cover letter, the second page requested basic
demographic data about the respondent, and the third
page contained the clinical scenarios or vignettes. [see
Additional file 1] For example, the stem, or base case, for
vignette #1 was, "A 22-yr-old woman status post outpa-
tient pelvic laparoscopy under general anesthesia. She
received no PONV prophylaxis. In the PACU, she reports
PONV. What would your antiemetic order(s) be?"
Questionnaire instructions included: "Assume all other
relevant clinical history and exam is negative. Assume
patients have received adequate analgesics." We did not
specify whether responders could use monotherapy or
combination therapy.
To assess how prophylaxis choice affected treatment, the
above vignette stem stayed the same for vignettes #2, #3,
#4 and #5, but the number of prophylaxis anti-emetics
increased from one to four. Vignette # 2 had the patient
receive a 5-HT3 anatagonist for prophylaxis, vignette # 3
had a 5-HT3 antagonist and metoclopromide for prophy-
laxis, and vignette #4 had a 5-HT3 antagonist, metoclo-BMC Anesthesiology 2006, 6:6 http://www.biomedcentral.com/1471-2253/6/6
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promide and dexamethasone. Vignette #5 stated, "A 22-
yr-old woman status post outpatient pelvic laparoscopy
under general anesthesia. She received a 5-HT3 antago-
nist, metoclopromide, dexamethasone, and droperidol
for prophylaxis. In the PACU, she reports PONV. What
would your antiemetic order(s) be?"
We also aimed to assess the second choice for treatment if
initial PONV treatment fails. For each vignette we asked,
"What is your second choice for treatment if the first treat-
ment fails?"
Four senior, board-certified anesthesiologists in the Stan-
ford Department of Anesthesiology reviewed the vignettes
to ensure adequate content.
Five other anesthesiologists (convenience sample) were
asked to take the questionnaire twice, two days apart, in a
non-random, non-anonymous fashion to assist with
checking the internal reliability of the questionnaire. All
five respondents answered every question. Of 90 eligible
responses (demographic questions were excluded), 82%
were answered the same way the second time.
95% two-sided confidence intervals were calculated for
N1/(N1+N2) using Clopper-Pearson method (StatXact-6,
Cytel Software Corporation, Cambridge, MA) [16].
Results
Of the 300 questionnaires mailed out, twenty-one were
returned as undeliverable because the person was no
longer at that address, and three were returned with the
respondent stating they were no longer in active clinical
practice. The 106 completed questionnaires returned gave
a response rate of 106/276 or 38%. (see Table 1 for demo-
graphics)
Sixty-seven % (95% confidence intervals, 62% – 79%) of
the anesthesiologists we surveyed reported they would
administer a 5-HT3 antagonist as first choice if no proph-
ylaxis had been administered. (Table 2) (Ondansetron
(53%) + dolasetron (13%) + granisetron (1%) = 67%)
Metoclopramide, with 11% (95% confidence intervals,
6.3% – 18%) of anesthesiologists choosing as first option,
and dexamethasone (8% of anesthesiologists, 95% confi-
dence intervals, 3.3% – 14%) were the next two most pop-
ular agents for PONV treatment when no prophylaxis had
been given.
Sixty-five % (95% confidence intervals, 55% – 74%) of
anesthesiologists would use non-pharmacologic interven-
tions for treatment. An IV fluid bolus or oxygen via nasal
cannula were the two most common choices. (Table 2)
PONV treatment choice changed depending on prophy-
laxis agent given. (Table 2) For example, only approxi-
mately 5% of anesthesiologists reported they would
repeat dose the metoclopramide, approximately 3%
would repeat the dexamethasone, and 7% would repeat
the droperidol. In contrast, when a 5-HT3 antagonist was
used for monotherapy prophylaxis, a repeat dose of the 5-
HT3 antagonist was administered by 26% (95% confi-
dence intervals, 18% – 36%) of survey responders. Pro-
methazine utilization increased as a treatment choice as
the number of other drugs (the 5-HT3 antagonist, meto-
clopramide, dexamethasone, and droperidol) for prophy-
laxis increased as stated in our vignettes. (Table 2)
If no prophylaxis was administered and initial therapy for
PONV failed, then the most common (reported by 24% of
anesthesiologists) next choice for treatment was still a 5-
HT3 antagonist, followed by promethazine.
Thirty-seven % of respondents wrote in some free text
under the comments section. Forty-four % of the com-
ments explained or reinforced answers given in the main
part of the questionnaire, while 33% of the written-in
comments related to droperidol availability and the FDA
Black Box warning. The remaining 23% of comments
Table 1: Demographics of respondents (N = 106)
Mean years in practice (SD, range) 19 (8, 3 – 41)
Mean age (SD, range) 47 (8, 31 – 68)
Primary practice location
Hospital-Inpatient 65%
Hospital-Outpatient 16%
Free-standing surgery center 17%
Surgeon office 1%
Male 85%
Practice Characteristics
Academic 43%
Private Practice 57%
% of practice that is ambulatory 52%
Number of states represented 19BMC Anesthesiology 2006, 6:6 http://www.biomedcentral.com/1471-2253/6/6
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referred to a variety of issues such as: formulary availabil-
ity, "I examine every patient. What I do depends on my
exam," "Need more treatment studies," and "Treatment
and choice are often driven by the nursing staff."
Discussion
Our written questionnaire study found that 5-HT3-antag-
onists are the most common choice for treatment of estab-
lished PONV when no prophylaxis is used. This pattern
holds true following PONV prophylaxis with a regimen
including a 5 HT3 antagonist regardless of the number of
prophylactic antiemetics received by the patient
Overall, anesthesiologists reported administering a total
of eighteen different drugs for PONV treatment and
twelve different non-pharmacologic interventions. Varia-
tions in medical practice such that physicians treat similar
patients differently may be created by uncertainty about
efficacy of interventions, or formulary restrictions, or
recent visits by the pharmaceutical sales representative, as
well as differences in practitioners' residency training,
judgment, and beliefs about drug acquisition costs and
side-effect profiles [17-19]. Enhanced education and indi-
vidualized feedback can change anesthesiologists' practice
patterns [20,21].
Initial treatment
According to responses to a specific question on the ques-
tionnaire, almost all anesthesiologists (96%) preferred
pharmacologic interventions for treatment, instead of
non-pharmacologic (e.g., hydration, oxygen, acupunc-
ture). The four anti-emetics chosen to be included for
Table 2: Initial treatment for PONV by the prophylaxis agent given
Vignettes with different prophylaxis regimens
None 5-HT3 5-HT3 & meto 5-HT3 & meto & dexa 5-HT3 & meto & dexa 
& drop
Pharmacologic treatment:
Ondansetron 53% 22% 23% 23% 23%
D o l a s e t r o n 1 3 % 3 %2 %5 %4 %
Droperidol 7% 14% 18% 19% 7%
Dexamethasone 8% 15% 19% 2% 3%
Metoclopramide 11% 21% 4% 5% 4%
Promethazine 3% 13% 20% 22% 28%
Prochlorperazine 0% 1% 1% 2% 4%
Diphenhydramine 0% 0% 0% 5% 4%
Intra-muscular 
ephedrine
1% 4% 4% 5% 5%
H y d r o x y z i n e1 %2 %2 %5 %4 %
Propofol 0% 1% 1% 2% 5%
S c o p o l a m i n e  p a t c h 1 %1 %1 %2 %3 %
Granisetron 1% 1% 1% 1% 1%
O t h e r 1 %2 %2 %2 %3 %
Total 100% 100% 100% 100% 100%
Other includes: trimethobenzamide, perphenazine, haloperidol, atropine, or midazolam
5-HT3 = 5-HT3-antagonist; meto = metoclopramide; dexa = dexamethasone; drop = droperidol
Non-pharmacologic treatment:
IV fluid bolus 57% 55% 56% 57% 51%
Oxygen nasal cannula 22% 19% 19% 19% 20%
Sniff alcohol swab 6% 5% 7% 7% 6%
Reassure the patient 
that PONV will pass
1% 3% 1% 1% 1%
F o r c e d  a i r  w a r m i n g 3 %4 %3 %3 %7 %
K e e p  N P O 1 %1 %3 %1 %1 %
Acupressure forearm 
& acupuncture & 
acustimulation with 
the ReliefBand
4% 4% 4% 4% 6%
Lay patient flat on 
gurney
4% 3% 3% 3% 3%
O t h e r 0 %5 %3 %3 %4 %
Total 100% 100% 100% 100% 100%
Other includes: encourage emptying of oropharynx/spitting, assure there is no bleeding, transfer to inpatient ward, or add glucose to IVBMC Anesthesiology 2006, 6:6 http://www.biomedcentral.com/1471-2253/6/6
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prophylaxis in the hypothetical patient vignettes – a 5-
HT3 antagonist, droperidol, dexamethasone, and meto-
clopramide – were intended to represent major receptor
systems involved in the etiology of PONV, as well as
agents commonly used in clinical practice. We did not
specify the doses of the four chosen antiemetics because
we were mainly interested in the choice not the dose. To
keep survey length reasonable, we opted not have a
vignette with promethazine as a prophylaxis agent
because in our outpatient practice promethazine is infre-
quently given for prevention.
Two-thirds of the anesthesiologists reported they would
administer a 5-HT3 antagonist as first choice for PONV
treatment if no prophylaxis had been given. The efficacy
of the 5-HT3 antagonists may be more pronounced when
a patient is vomiting than as treatment for nausea. There
is weak evidence of dose-responsiveness with these drugs
[22,23]. Therefore, small doses of the 5-HT3 antagonists
(ondansetron 1 mg) have been recommended for treat-
ment. Interestingly, less than 15% of anesthesiologists
reported using a combination of several agents for treat-
ment, despite that combination of agents, or multi-modal
therapy, may be increasingly being used for prophylaxis.
Repeat dosing
A majority of anesthesiologists reported they changed to a
different agent for PONV treatment than the one(s) used
for prophylaxis. However, 26% of practitioners would
administer a second dose of the 5HT-3 antagonist
(ondansetron (22%) + dolasetron (3%) + granisetron
(1%)) if initial 5HT-3 antagonist prophylaxis failed. This
is despite consensus guidelines, mostly derived from
expert opinion not clinical trials, which suggest that if
PONV occurs within six hours postoperatively, patients
should not receive a repeat dose of the prophylactic
antiemetic. Prescribing information for ondansetron
states that a second dose does not provide additional con-
trol if the first prophylactic dose has failed. A drug from a
different class should be used for treatment [24].
Pharmacogenomics may affect the success of a 5-HT3
antagonist because some patients have extra copies of the
CYP2D6 gene, a genotype consistent with ultrarapid
metabolism [25]. A separate study of patients who failed
prophylaxis with ondansetron found the complete
response rate was significantly higher after treatment with
promethazine (78%) than after treatment with repeat
ondansetron (46%) [26]. A third study of 428 patients (of
2,199 prophylactically treated with ondansetron) with
PONV in the PACU, found that an additional dose of
ondansetron was no better than placebo for reducing
PONV two hours postoperatively [27].
Interestingly, anesthesiologists in our survey study were
less likely to redose metoclopramide, dexamethasone, or
droperidol for treatment (than a 5-HT3 antagonist) if any
of those agents were administered for prophylaxis.
One quarter of anesthesiologists reported not having pre-
printed PACU orders specifically for PONV. This may
increase the variability in PONV clinical practice, and
make it difficult for evidence-based care to be imple-
mented. Better mechanisms for delivering decision clini-
cal support (e.g., evidence based guidelines) for PONV in
the PACU may be possible. Four % of our sample volun-
tarily indicated that their group had developed their own
PONV treatment guidelines.
For "older generation" antiemetics there are few data on
therapeutic efficacy for established PONV. As an example,
in patients who failed prophylaxis with droperidol, the
complete response rate was significantly higher after treat-
ment with promethazine (77%) than after droperidol
(56%) [26].
It may be that anesthesiologists believe that interventions
shown to be effective for prevention will be similarly
effective for treatment. For example, many of our
responders indicated they would use supplemental oxy-
gen to treat PONV, but most studies of oxygen have been
for PONV prevention, with varying efficacy [28,29]. Other
non-pharmacologic treatments suggested by our respond-
ents such as IV fluid therapy, isopropyl alcohol inhalation
and acupuncture/acustimulation have been studied,
sometimes for prophylaxis not treatment, while others
such as forced air warming have not [30,31].
Beyond six hours, PONV can be treated a second time
with any of the agents used for prophylaxis except dexam-
ethasone and scopolamine, which are longer acting. We
found that 73% of anesthesiologists reported having pre-
printed PACU orders for PONV at their primary practice
location such that the anesthesiologist can amend the
orders via checkbox, or by writing in.
To keep the questionnaire a reasonable length, we did not
ask respondents why they chose the different treatments.
The next study will assess if choices are based on such
items as department policy, cost considerations, perceived
lack of evidence or insufficient knowledge on the part of
the anesthesiologist, individual patient's condition, or
nursing determination.
PONV treatment research requires more precise PONV 
assessment
The lack of consistent assessment of PONV is an issue
because studies often define endpoints differently. Nau-
sea sometimes is defined by patient self-report, and otherBMC Anesthesiology 2006, 6:6 http://www.biomedcentral.com/1471-2253/6/6
Page 6 of 7
(page number not for citation purposes)
times as an observer asking the patient a yes/no answer.
Some institutions define PONV as when actual treatment
of PONV occurs, which is easily quantified, but is con-
founded because patients' perceptions of nausea severe
enough to require intervention varies among patients, and
nurses have different thresholds for initiating treatment
[32]. Often nausea and vomiting are not distinguished
and the symptoms of PONV are combined into a single
PONV endpoint [33]. The challenge of multiple end-
points and heterogeneity of definitions need to be
addressed before aiming to establish the optimal manage-
ment of PONV once it occurs in the PACU. The entire
observation period should cover 24 hrs [34]. Treatment
responses we obtained might have varied between a
patient developing nausea alone or having vomiting.
Limitations
To control for the potential impact of biases from differ-
ing case-mix, we employed a postal questionnaire vignette
methodology. The limitations of this method include that
the subject sample depended on anesthesiologists' will-
ingness to participate [35]. While not significantly differ-
ent from other national surveys of professional
organizations, the response rate of 38 % is low and non-
response bias may exist. This bias reflects the fraction of
eligible subjects that do not respond and the difference in
their answers compared to responders. Since it is
unknown whether the physicians answering the question-
naire were systematically different from non-responders,
there is no absolutely acceptable level of response.
The study had relatively small sample size. Determination
of adequate sample size may be difficult and depends on
the desired precision of the results. A larger number of
respondents is always possible (to enable subgroup anal-
yses about differences among practice types, academic vs.
private practice, for example) but we obtained a reasona-
ble sampling of current practice patterns to help design
larger studies of PONV treatment.
Also, our result that a 5-HT3 antagonist is the most com-
monly prescribed for PONV treatment may not be appli-
cable in other countries.
Although vignettes are suitable for comparative analyses
because they control for case-mix, further studies are
needed to confirm that the results from vignette-based
questionnaires are in fact a valid measure of the real-life
clinical care provided by anesthesiologists. The open-
ended comments section in our questionnaire did not
uncover any problems with anesthesiologists stating they
didn't understand the questionnaire, or that key elements
were missing. Since our vignettes were hypothetical, the
answers provided by the anesthesiologists may not be
what they actually use.
Conclusion
5-HT3-antagonists are the most common choice for treat-
ment of established PONV for outpatients when no
prophylaxis is used, and also following prophylactic regi-
mens that include a 5HT3 antagonist, regardless of the
number of prophylactic antiemetics given. Whereas 3%–
7% of anesthesiologists would repeat dose metoclopra-
mide, dexamethasone, or droperidol, 26% of practition-
ers would re-dose the 5-HT3-antagonist for PONV
treatment. PONV guidelines may help reduce this unnec-
essary redosing.
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